37 results for Apixaban Sort: Relevance | Date
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism (VTE) after total hip or knee replacement in adults
This guideline covers diagnosing and managing atrial fibrillation in adults. It aims to ensure that people receive the best management to help prevent harmful complications, in particular stroke and bleeding.
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation (AF)
Everything NICE has said on assessing, diagnosing, treating and reducing the risk of venous thromboembolism in adults in an interactive flowchart
This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.
Everything NICE has said on diagnosing and managing atrial fibrillation in an interactive flowchart
the use of the 4 non-vitamin K antagonist oral anticoagulants (NOACs), apixaban, dabigatran etexilate, edoxaban and rivaroxaban, in...
Recommendation ID TA245/1 Question More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and knee
research on the management of bleeds that occur while people are receiving apixaban, rivaroxaban or dabigatran etexilate, as there are...
Everything NICE has said on structural heart defects in an interactive flowchart
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
NICE block scoping reports
This guideline covers cardiac rehabilitation and preventing further cardiovascular disease in people aged 18 and over who have had a myocardial infarction. It aims to promote the health of people who have had an MI by encouraging them to attend a cardiac rehabilitation programme and advising them on a healthy lifestyle. It also includes advice on drug therapy.
NICE technology appraisal guidance static list
In development [GID-TAG419] Expected publication date: TBC
2015, as Deputy CEO. Jo has sat on NICE STAs and Scoping workshops for Apixaban, Dabigatran, Dronedarone, Rivaroxaban and Vernakalent...
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on point-of-care coagulometers (the CoaguChek XS system) to self-monitor blood clotting
Evidence-based recommendations on edoxaban (Lixiana) for treating and preventing deep vein thrombosis (DVT) and pulmonary embolism
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing adverse outcomes after acute management of acute coronary syndrome (ACS)
This guideline covers diagnosing, assessing, managing and monitoring anaemia in people with chronic kidney disease. It aims to improve care for people with chronic kidney disease by specifying how to assess when their anaemia needs treating, and by making detailed recommendations on treatment with erythropoietic stimulating agents (ESAs) and iron. It also covers detecting and managing ESA-resistant anaemia.
This guideline covers the care and treatment of people with, or at risk of developing, chronic kidney disease. It aims to prevent or delay the progression of chronic kidney disease, reduce or prevent the development of complications, and reduce the risk of cardiovascular disease.
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism
Evidence-based recommendations on dual-chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
Advice on the use of the AliveCor Heart Monitor and AliveECG (Kardia Mobile) app for detecting atrial fibrillation (AF) to aid local decision-making
TA245/1 | More trials of apixaban compared with other low molecular weight heparin (LMWHs) in total hip and
Offering patients anticoagulants could help prevent thousands of strokes and premature deaths from atrial fibrillation (AF), according to NICE.
As NICE publishes its 300th technology appraisal, we look back at the impact they have had on patient care.
One of NICE?s regular functions is to produce recommendations on the use of new and existing medicines and treatments in the NHS.
Patients with atrial fibrilation can now be offered apixaban (Eliquis) as an alternative to warfarin to reduce the risk of stroke and blood clots, says NICE.
Thousands of strokes and deaths due to atrial fibrillation could be prevented each year by ensuring patients receive effective anticoagulant drugs, according to updated guidance from NICE.
Adults with atrial fibrillation (AF) should be prescribed newer medications instead of aspirin for the prevention of stroke, says NICE.
A quick look at the guidance and advice that has generated the most interest during the first half of the year.